Recent Trends in Cardiology

At the recent ESC Congress 2025, two groundbreaking trials highlighted the effectiveness of cardiac myosin inhibitors in treating hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes abnormally thick. This new class of drugs is generating significant buzz in the cardiology community and could soon change the way doctors approach treatment. A Head-to-Head Win The MAPLE-HCM trial compared the cardiac myosin inhibitor aficamten against the traditional beta-blocker metoprolol in patients with obstructive HCM. The results were a major win for aficamten, which proved to be superior in improving exercise capacity and symptoms. This is a big deal because it suggests that aficamten could be a more effective first-line treatment than the current standard of care. Mixed Results, More to Learn A second trial, the ODYSSEY-HCM trial, explored the use of another cardiac myosin inhibitor, mavacamten, in patients with non-obstructive HCM. The study found that mavacamten did not...